Patients who require anticoagulation with warfarin or equivalent vitamin K antagonists are not eligible
Participants with ongoing anticoagulation treatment with warfarin or equivalent vitamin K antagonists (example phenprocoumon), or ongoing treatment with agents known to be strong CYPA/ inhibitors, or has taken any disallowed therapies as noted in Section ., Prohibited Medications, before the planned first dose of study drug
Treatment with warfarin or other vitamin K antagonists (eg, phenprocoumon)
Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon); patients may be eligible if able to be taken off warfarin and started on an alternative anticoagulant
Requires anticoagulation with warfarin or other vitamin K antagonists
Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g. phenprocoumon)
Systemic anticoagulation with warfarin or other Vitamin K antagonists.
Requires vitamin K antagonists. Note: Patients receiving low doses prescribed to maintain the patency of venous access devices may be included. Factor Xa antagonists are permitted.
Requires therapeutic anticoagulation with warfarin or other vitamin K antagonists
Requires or is currently receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within  days of first dose of study drug
Requires anticoagulation with warfarin or equivalent vitamin K antagonists
Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon)
Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon)
Requires anticoagulation with warfarin or equivalent vitamin K antagonists
Requires anticoagulation with warfarin or equivalent vitamin K antagonist
Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon)
Relapsed/refractory MCL: Requires anticoagulation with warfarin or equivalent vitamin K antagonist
Newly diagnosed MCL: Requires concomitant anticoagulation with warfarin or equivalent vitamin K antagonist
Patients who require warfarin or other vitamin K antagonists for anticoagulation (other anticoagulants are allowed after consultation with the principal investigator)
Requires anticoagulation with warfarin or equivalent vitamin K antagonists
Need for anticoagulation with a vitamin K antagonist (warfarin); other anticoagulants and\r\nantiplatelet agents are allowed
Requires concomitant anticoagulation with warfarin or equivalent vitamin K antagonist.
Received anticoagulation therapy with warfarin, or equivalent vitamin K antagonists, within the last  days prior to day  of ibrutinib; patients with familial coagulopathic diseases (e.g. hemophilia, von Willebrand disease) are also excluded; if applicable, subjects must discontinue fish oil and vitamin E supplements within  days prior to initiating ibrutinib therapy
Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within  days of first dose of study drug.
Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within  days of first dose of study drug.
Treatment by warfarin or equivalent vitamin K antagonists.
Therapeutic anticoagulation with Vitamin-K antagonists (eg, warfarin) or with heparins and heparinoids. o However, prophylactic anticoagulation as described below is allowed:
Subjects requiring anticoagulation with warfarin or vitamin K antagonists are excluded from the ibrutinib arm; if previously on these drugs and switched, international normalized ratio (INR) must be normal for  days prior to enrollment
Requirement for anticoagulation with warfarin or similar vitamin K antagonists
Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon); if patients have been on warfarin or equivalent vitamin K antagonists in the past, they will not be eligible if administered within  days of the first dose of study drug
Patients who require warfarin anticoagulation or who have received warfarin or equivalent vitamin K antagonists =<  days prior to treatment day ; patients may be eligible if able to be taken off warfarin and started on an alternative anticoagulant
Requires treatment with anticoagulation with warfarin or equivalent vitamin K antagonists
Requires anticoagulation with warfarin or equivalent vitamin K antagonist
Subjects that have received anticoagulation therapy with warfarin or equivalent vitamin K antagonists within the last  days are not eligible
Requires anticoagulation with warfarin or equivalent Vitamin K antagonists
Patients requiring any therapeutic anticoagulation are excluded; patients who have received warfarin or other vitamin K antagonists within  days or are taking warfarin or other vitamin K antagonists are not eligible
Requires or is receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g.: phenprocoumon) within  days of the first dose of study drug
Requires anticoagulation with warfarin or equivalent vitamin K antagonists
Requires anticoagulation with warfarin or equivalent vitamin K antagonists or treatment with strong CYPA/ inhibitors
Patients requiring anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within  days from the start of study drug cannot be treated with ibrutinib but idelalisib would be an option
Requires anticoagulation with warfarin or equivalent vitamin K antagonists
Received anticoagulation therapy with warfarin or equivalent vitamin K antagonists within the last  days
Anticoagulation with warfarin or equivalent vitamin K antagonists within  days prior to starting ibrutinib and throughout the study
Prothrombin time (PT) >. x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin)
Received anticoagulation therapy with Coumadin or equivalent vitamin K antagonists within the last  days
Anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon); Note: use of low molecular weight heparin (or any anticoagulation agent) is allowed provided there is no history of bleeding (minor or major) =<  months prior to registration; the treating physician should discuss the case with the study chair
Treatment with warfarin or other vitamin K antagonists; patients who are on active treatment with warfarin or other vitamin K antagonists for conditions requiring anticoagulation will be switched, when not contraindicated, to a different form of anticoagulation, including low molecular weight heparin (LMWH)s (ex: enoxaparin, dalteparin) or oral anti-Xa drugs (ex: rivaroxaban or apixaban) Patients who switch to these alternative forms of anticoagulation will be eligible
Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon)
Patients who require warfarin or other vitamin K antagonists for anticoagulation (other anticoagulants are allowed after consultation with the principal investigator)
Patients who require warfarin or other vitamin K antagonists for anticoagulation (other anticoagulants are allowed)
Requires anticoagulation with warfarin or other vitamin K antagonists
